Pfizer (PFE) reported $15.03 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 2.6%. EPS of $0.77 for the same period compares to $0.78 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $14.45 billion, representing a surprise of +4.04%. The company delivered an EPS surprise of +13.24%, with the consensus EPS estimate being $0.68.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Revenues- Specialty Care- Cibinqo- United States: $34 million compared to the $30 million average estimate based on two analysts. The reported number represents a change of +41.7% year over year.
- Revenues- Primary Care- Comirnaty- Total International: $223 million versus $165.71 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.8% change.
- Revenues- Specialty Care- United States: $1.68 billion versus the two-analyst average estimate of $1.5 billion. The reported number represents a year-over-year change of -19.5%.
- Revenues- Specialty Care- Total International: $1.68 billion versus $1.7 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -27% change.
- Revenues- Oncology- Ibrance- Worldwide: $1.06 billion versus the two-analyst average estimate of $1.05 billion. The reported number represents a year-over-year change of +0.9%.
- Revenues- Specialty Care- Xeljanz- Worldwide: $251 million versus $227.94 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -22.1% change.
- Revenues- Specialty Care- Inflectra- Worldwide: $171 million versus the two-analyst average estimate of $108.59 million. The reported number represents a year-over-year change of +23%.
- Revenues- Primary Care- Eliquis- Worldwide: $2.43 billion versus the two-analyst average estimate of $1.98 billion. The reported number represents a year-over-year change of +21.1%.
- Revenues- Pfizer CentreOne- Worldwide: $373 million versus the two-analyst average estimate of $326.17 million. The reported number represents a year-over-year change of +13.7%.
- Revenues- Pfizer Biopharma- Worldwide: $14.66 billion compared to the $14.09 billion average estimate based on two analysts. The reported number represents a change of +2.5% year over year.
- Revenues- Specialty Care- Vyndaqel family- Worldwide: $1.76 billion versus the two-analyst average estimate of $1.75 billion. The reported number represents a year-over-year change of +9.1%.
- Revenues- Primary Care- Comirnaty- Worldwide: $261 million versus $278.14 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -31.5% change.
View all Key Company Metrics for Pfizer here>>>
Shares of Pfizer have returned +5.5% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpPfizer Inc. (PFE) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
